These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 12667227)

  • 21. Impact of mass chemotherapy in domestic livestock for control of zoonotic T. b. rhodesiense human African trypanosomiasis in Eastern Uganda.
    Fyfe J; Picozzi K; Waiswa C; Bardosh KL; Welburn SC
    Acta Trop; 2017 Jan; 165():216-229. PubMed ID: 27570206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A returning traveller with fever, facial swelling, and skin lesions.
    Richter J; Göbels S; Göbel T; Westenfeld R; Müller-Stöver I; Häussinger D
    BMJ; 2012 Mar; 344():e2092. PubMed ID: 22442353
    [No Abstract]   [Full Text] [Related]  

  • 23. In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness.
    Schmid C; Kuemmerle A; Blum J; Ghabri S; Kande V; Mutombo W; Ilunga M; Lumpungu I; Mutanda S; Nganzobo P; Tete D; Mubwa N; Kisala M; Blesson S; Mordt OV
    PLoS Negl Trop Dis; 2012; 6(11):e1920. PubMed ID: 23209861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Delivery of antihuman African trypanosomiasis drugs across the blood-brain and blood-CSF barriers.
    Sekhar GN; Watson CP; Fidanboylu M; Sanderson L; Thomas SA
    Adv Pharmacol; 2014; 71():245-75. PubMed ID: 25307219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eflornithine for the treatment of human African trypanosomiasis.
    Burri C; Brun R
    Parasitol Res; 2003 Jun; 90 Supp 1():S49-52. PubMed ID: 12811548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo.
    Kazumba LM; Kaka JT; Ngoyi DM; Tshala-Katumbay D
    PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006504. PubMed ID: 29897919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug resistance in human African trypanosomiasis.
    Barrett MP; Vincent IM; Burchmore RJ; Kazibwe AJ; Matovu E
    Future Microbiol; 2011 Sep; 6(9):1037-47. PubMed ID: 21958143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo.
    Balasegaram M; Harris S; Checchi F; Hamel C; Karunakara U
    Bull World Health Organ; 2006 Oct; 84(10):777-82. PubMed ID: 17128357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. State of the art in African trypanosome drug discovery.
    Jacobs RT; Nare B; Phillips MA
    Curr Top Med Chem; 2011; 11(10):1255-74. PubMed ID: 21401507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
    Wenzler T; Boykin DW; Ismail MA; Hall JE; Tidwell RR; Brun R
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4185-92. PubMed ID: 19620327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro and in vivo evaluation of 28DAP010, a novel diamidine for treatment of second-stage African sleeping sickness.
    Wenzler T; Yang S; Patrick DA; Braissant O; Ismail MA; Tidwell RR; Boykin DW; Wang MZ; Brun R
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4452-63. PubMed ID: 24867978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification and Characterization of FTY720 for the Treatment of Human African Trypanosomiasis.
    Jones AJ; Kaiser M; Avery VM
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1859-61. PubMed ID: 26666915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-alpha-difluoromethylornithine (DFMO).
    Iten M; Matovu E; Brun R; Kaminsky R
    Trop Med Parasitol; 1995 Sep; 46(3):190-4. PubMed ID: 8533023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness).
    Kennedy PG
    Lancet Neurol; 2013 Feb; 12(2):186-94. PubMed ID: 23260189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness.
    Bisser S; N'Siesi FX; Lejon V; Preux PM; Van Nieuwenhove S; Miaka Mia Bilenge C; Būscher P
    J Infect Dis; 2007 Feb; 195(3):322-9. PubMed ID: 17205469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The rise and fall of sleeping sickness.
    Barrett MP
    Lancet; 2006 Apr; 367(9520):1377-8. PubMed ID: 16650633
    [No Abstract]   [Full Text] [Related]  

  • 37. A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda.
    Kansiime F; Adibaku S; Wamboga C; Idi F; Kato CD; Yamuah L; Vaillant M; Kioy D; Olliaro P; Matovu E
    Parasit Vectors; 2018 Feb; 11(1):105. PubMed ID: 29471865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study.
    Kuemmerle A; Schmid C; Bernhard S; Kande V; Mutombo W; Ilunga M; Lumpungu I; Mutanda S; Nganzobo P; Tete DN; Kisala M; Burri C; Blesson S; Valverde Mordt O
    PLoS Negl Trop Dis; 2021 Nov; 15(11):e0009903. PubMed ID: 34748572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [In vivo resistance to strains of Trypanosoma rhodesiense, Mozambique, 1985].
    Pérez Martín O; Lastre González M; Urban M; Shwalbach J
    Rev Cubana Med Trop; 1991; 43(3):189-93. PubMed ID: 9768188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment options for second-stage gambiense human African trypanosomiasis.
    Eperon G; Balasegaram M; Potet J; Mowbray C; Valverde O; Chappuis F
    Expert Rev Anti Infect Ther; 2014 Nov; 12(11):1407-17. PubMed ID: 25204360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.